New immune cell therapy shows promise for Tough-to-Treat colon cancer
NCT ID NCT04444622
First seen Nov 01, 2025 · Last updated May 02, 2026 · Updated 25 times
Summary
This study tested a new immunotherapy called STIMVAX in 29 adults with metastatic colorectal cancer that had not responded to two prior treatments. STIMVAX uses immune cells from healthy donors to help the body fight cancer. The main goals were to see how long patients lived and to check for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hirschfield Oncology Center
The Bronx, New York, 10469, United States
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
Mt. Sinai Comprehensive Cancer Center
Miami Beach, Florida, 33140, United States
-
Summit Health
Florham Park, New Jersey, 07932, United States
Conditions
Explore the condition pages connected to this study.